Shanghai Jizhi Biochemical Technology Co., Ltd
China
Product Name: Ipriflavone
Price: ￥218.0/5g
Purity: 97.0%
Stocking Period: 2 Day
Contact: Liu jia

DC Chemicals Limited
China
Product Name: Ipriflavone
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: Ipriflavone
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

Henan Tianfu Chemical Co., Ltd.
China
Product Name: Ipriflavone
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson

35212-22-7

35212-22-7 structure

Name: Ipriflavone
Chemical Name: ipriflavone
CAS Number: 35212-22-7
Molecular Formula: C₁₈H₁₆O₃
Molecular Weight: 280.318
Catalog: API Water, electrolyte and acid-base balance regulator Electrolyte balance regulator
Create Date: 2018-09-03 04:18:32
Modify Date: 2024-01-02 19:45:59
Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.

Name	ipriflavone
Synonyms	MFCD00221719 Iprosten 3-phenyl-7-(propan-2-yloxy)-4H-chromen-4-one Osteofix 7-Isopropoxyisoflavone 3-phenyl-7-propan-2-yloxychromen-4-one 4-isopropoxyisoflavone 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one Ipriflavone (JAN) 7-Isopropoxy-3-phenyl-4H-chromen-4-one Ipriflavone 7-isopropoxy-isoflavone 7-isopropyloxy-isoflavone Osten Yambolap Ipriflavone (Osteofix) FL-113 Osteoquine EINECS 201-641-0 7-Isopropoxy-3-phenylchromone 4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl-

Description	Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease Natural Products >> Flavonoids
In Vitro	Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells and blocks the ligand-induced phosphorylation of Tyr(845) of the EGFR. Ipriflavone does not promote apoptosis of MDA-231 cells[1]. Ipriflavone also promotes the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like cells as well as the activity of alkaline phosphatase[2].
In Vivo	Daily oral administration of ipriflavone at 12 mg/mouse significantly inhibits the development of new osteolytic bone metastases and the progression of established osteolytic lesions, prolonging the life of tumor-bearing mice. Ipriflavone reduces the number of osteoclasts at the bone-cancer interface with no severe adverse effects on the host[1]. 1-month treatment with ipriflavone increases bone density and improves the biomechanical properties of adult rat male bones without altering mineral composition[3]
Cell Assay	Ipriflavone is dissolved in absolute ethanol and added to the medium at 1-50 μM. The final ethanol concentrations are <0.5% (v/v). MDA-231 cells are seeded in 35 mm culture dishes in DMEM supplemented with 10% FBS in the presence of ipriflavone (1, 10 or 50 μM) or ethanol. After 48 hr incubation, the medium is changed with fresh medium containing the same concentrations of ipriflavone or ethanol. After incubation for 24, 48, 72 and 96 hr from the initial seeding, cells are treated with trypan blue to estimate the number of viable cells[1].
Animal Admin	Rats: To assess the potential impact of ipriflavone on the biomechanical properties and mineral composition of bone, adult male rats are orally administered two doses (200 or 400 mg/kg bw) of ipriflavone for 1 month. Bone biomechanics are evaluated by vibration damping, an index of strain energy loss, and impact strength[3]. Mice: Ipriflavone is suspended in water containing 0.5% (w/v) methylcellulose and given to mice orally at 6 or 12 mg/0.2 mL daily, which is equivalent to 200 or 400 mg/kg body weight. MDA-231 cells are injected s.c. into the interscapular space of nude mice (on day 0), which are then given ipriflavone (6 or 12 mg/mouse) or the methylcellulose solution orally from day 1 to day 27. Tumor growth is analyzed twice a week by measuring the tumor volume[1].
References	[1]. Iisaki T, et al. Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model. Int J Cancer. 2002 Aug 1;100(4):381-7. [2]. Hagiwara H, et al. Ipriflavone down-regulates endothelin receptor levels during differentiation of rat calvarial osteoblast-like cells. J Biochem. 1999 Jul;126(1):168-73. [3]. Civitelli R, et al. Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcif Tissue Int. 1995 Mar;56(3):215-9.

Density	1.2±0.1 g/cm3
Boiling Point	435.9±45.0 °C at 760 mmHg
Melting Point	116-120 °C(lit.)
Molecular Formula	C₁₈H₁₆O₃
Molecular Weight	280.318
Flash Point	209.3±15.1 °C
Exact Mass	280.109955
PSA	39.44000
LogP	4.37
Vapour Pressure	0.0±1.0 mmHg at 25°C
Index of Refraction	1.592

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DJ3100500

CHEMICAL NAME :: 4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl-

CAS REGISTRY NUMBER :: 35212-22-7

LAST UPDATED :: 199612

DATA ITEMS CITED :: 6

MOLECULAR FORMULA :: C18-H16-O3

MOLECULAR WEIGHT :: 280.34

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 20,228,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >10 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 20,228,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 20,228,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 3185 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: KHFZAN Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1- 1967- Volume(issue)/page/year: 24(9),38,1990

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >10 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 20,228,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 20,228,1989

Hazard Codes	Xi
Risk Phrases	R36/37/38
Safety Phrases	S24/25
RIDADR	NONH for all modes of transport
WGK Germany	2
RTECS	DJ3100500
HS Code	2932999099

13057-72-2

75-26-3

~94%

35212-22-7

Literature: Oetvoes, Ferenc; Toth, Geza; Szatmari, Istvan; Levai, Ferenc Journal of Labelled Compounds and Radiopharmaceuticals, 1999 , vol. 42, # 5 p. 497 - 504

13057-72-2

75-26-3

78-92-2

~96%

35212-22-7

Literature: Erregierre S.p.A. Patent: US5973169 A1, 1999 ;

75-30-9

13057-72-2

~96%

35212-22-7

Literature: Vasil'ev, S.A.; Golubushina, G.M.; Kabachnyi, V.I.; Luk'yanchikov, M.S.; Molchanov, G.I.; et al. Pharmaceutical Chemistry Journal, 1990 , vol. 24, # 9 p. 641 - 645 Khimiko-Farmatsevticheskii Zhurnal, 1990 , vol. 24, # 9 p. 38 - 41

1092975-69-3

~93%

35212-22-7

Literature: Muthukrishnan; Singh, Om V. Synthetic Communications, 2008 , vol. 38, # 22 p. 3875 - 3883

3669-41-8

35212-22-7

Literature: Bioorganic and Medicinal Chemistry, , vol. 11, # 18 p. 4069 - 4081

Precursor 6
13057-72-2 75-26-3 78-92-2 75-30-9
1092975-69-3 3669-41-8
DownStream 5
13057-72-2 102805-96-9 97846-18-9 50561-04-1
65-85-0

HS Code	2914509090
Summary	HS:2914509090 other ketones with other oxygen function VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:5.5% General tariff:30.0%